What is Phlow?
Phlow operates as a modern contract development and manufacturing organization (CDMO) dedicated to bringing life-saving medicines to market through innovative scientific expertise and tech-enabled processes. The company's core mission involves enhancing the domestic supply chain for critical pharmaceutical ingredients, thereby reducing reliance on foreign manufacturing and bolstering national health resilience. By focusing on drug substance development and employing environmentally conscious manufacturing techniques, Phlow aims to decrease waste and shorten the time from discovery to patient access, contributing to healthier communities.
How much funding has Phlow raised?
Phlow has raised a total of $107M across 4 funding rounds:
Unspecified
$15M
Series A
$20M
Series B
$35M
Series C
$37M
Unspecified (2020): $15M, investors not publicly disclosed
Series A (2021): $20M, investors not publicly disclosed
Series B (2023): $35M, investors not publicly disclosed
Series C (2025): $37M featuring Align Private Capital
Key Investors in Phlow
Align Private Capital
Align Private Capital is a women-owned investment advisor specializing in alternative investments for Single Family Offices, leveraging a network of SFOs and sector experts to source direct investment opportunities.
What's next for Phlow?
With the infusion of $107M in total capital and a recent major strategic investment of $37M, Phlow is poised for significant expansion and operational enhancement. This substantial backing is expected to fuel advancements in its manufacturing capabilities, potentially enabling the company to scale its operations to meet increasing demand for domestic pharmaceutical production. The company's commitment to innovation and sustainability suggests a strategic focus on further developing its proprietary technologies and expanding its service offerings to government and private industry clients, solidifying its position as a leader in the evolving landscape of pharmaceutical manufacturing.
See full Phlow company page
